Lesson plan

Cebaracetam

Cebaracetam ( ; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed. It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. The mechanism of action of cebaracetam is undefined or unknown. The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. It reached phase 2 clinical trials prior to its discontinuation.

Back to article

Article summary

Cebaracetam ( ; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed. It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. The mechanism of action of cebaracetam is undefined or unknown. The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. It reached phase 2 clinical trials prior to its discontinuation.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.